The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse

Transplantation

Volumn 84, Issue 9, 2007, Pages 1204-1207

  Bueno, Valquiria ^a   Binet, Isabelle ^a   Steger, Ulrich ^a   Bundick, Robert ^b   Ferguson, Douglas ^b   Murray, Clare ^b   Donald, David ^b   Wood, Kathryn ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Immunosuppression; Monocarboxylate transporter; Rejection; Transplant arteriosclerosis

Indexed keywords

ALLOANTIBODY; ARC 117977; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; AORTA GRAFT; ARTERIOSCLEROSIS; ARTICLE; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; GRAFT SURVIVAL; HEART TRANSPLANTATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; SURVIVAL TIME; TRANSPLANTATION;

ANIMALS; AORTA; GRAFT SURVIVAL; HEART TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MONOCARBOXYLIC ACID TRANSPORTERS; SYMPORTERS; TRANSPLANTATION, HOMOLOGOUS;

EID: 36248932713     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000287543.91765.41     Document Type: Article

References (13)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
2. Guile SD, Bantick JR, Cheshire DR, et al. Potent blockers of the monocarboxylate transporter MCT1: Novel immunomodulatory compounds. Bioorg Med Chem Lett 2006; 16: 2260.
3. Guile SD, Bantick JR, Cooper ME, et al. Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties. J Med Chem 2007; 50: 254.
4. Halestrap A, Price N. The proton-linked monocarboxylate transporter (MCT) family: Structure, function and regulation. Biochem J 1999; 343: 281.
5. Murray C, Bantick J, Belfield G, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol 2005; 1: 371.
6. Ekberg H, Qi Z, Pahlman C, et al. The specific monocarboxylate transporter-1 (MCT-1) inhibitor, AR-C117977, reduces acute and chronic allograft rejection and inducs operational tolerance in the rat. Transplantation 2007; 84: 1191.
7. van Maurik A, Wood KJ, Jones N. Impact of both donor and recipient strains on cardiac allograft survival after blockade of the CD40-CD154 costimulatory pathway. Transplantation 2002; 74: 740.
8. Superina RA, Peugh WN, Wood KJ, Morris PJ. Assessment of primarily vascularized cardiac allografts in mice. Transplantation 1985; 42: 226.
9. Hara M, Kingsley C, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
10. Ensminger SM, Spriewald BM, Sorensen HV, et al. Critical Role for IL-4 in the Development of Transplant Arteriosclerosis in the Absence of CD40-CD154 Costimulation. J Immunol 2001; 167: 532.
11. Ensminger S, Witzke O, Spriewald B, et al. CD8+ T cells contribute to the development of transplant ateriosclerosis despite CD154 blockade. Transplantation 2000; 69: 2609.
12. Ikonen T, Gummert J, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969.
13. Mauiyyedi S, Pelle P, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574.